Question 1

What is IMNN-001?

Accepted Answer

IMNN-001 is a Other.

Question 2

How often does IMNN-001 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was IMNN-001 first tracked by Ergen?

Accepted Answer

First tracked on May 06, 2025.

Question 4

When was IMNN-001 last mentioned in news?

Accepted Answer

Last active on Jun 18, 2025.

Question 5

What is IMNN-001's current news sentiment?

Accepted Answer

Aggregate sentiment score: 90 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is IMNN-001 in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving IMNN-001?

Accepted Answer

IMUNON IMNN-001 Ovarian Cancer Breakthrough (May 06, 2025, 6 articles).

Question 8

How did the "IMUNON IMNN-001 Ovarian Cancer Breakthrough" event impact IMNN-001?

Accepted Answer

IMNN-001 is IMUNON's lead DNA-mediated immunotherapy candidate for advanced ovarian cancer. The positive Phase 2 OVATION 2 Study results, including improved overall survival and progression-free survival, validate its potential as a novel treatment and have propelled it into Phase 3 development.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.